

References

I-161

1. Chang T, Shiah H, Yang C, Yeh K, Cheng A, Shen B, Wang Y, Yeh C, Chiang N, Chang J, Chen L. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. *Cancer Chemotherapy and Pharmacology*. 2015 (75): 579-586.
2. Merrimack Pharmaceuticals. Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (NAPOLI-1). NLM Identifier NCT01494506. Last updated June 16, 2016.
3. S. Food and Drug Administration (FDA). FDA approves new treatment for advanced pancreatic cancer. FDA News Release. October 22, 2015.
4. European Society for Medical Oncology. EMA Recommends Granting a Marketing Authorisation for Pegylated Liposomal Formulation of Irinotecan for Metastatic Pancreatic Adenocarcinoma. It is intended in combination with 5-FU and LV in patients who have progressed following gemcitabine based therapy. July 2016.
5. NCCN Drugs & Biologics Compendium™. ONIVYDE® (irinotecan liposome injection) Version 1.2020. National Comprehensive Cancer Network (NCCN).
6. Micromedex DrugDex Compendium®. 2020. Irinotecan Liposome (Onivyde).
7. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Irinotecan Liposomal.
8. Onivyde (irinotecan liposome) for intravenous use [package insert]. Ipsen Biopharmaceuticals, Inc. Basking Ridge, NJ. Revised 06/2017
9. Koeller J, Surinach A, Arikian S.R. et. al. Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan. *Therapeutic Advances in Medical Oncology*, 2020:
10. Wang-Gillam A, Hubner RA, Siveke, JT et. al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. *European Journal of Cancer*, 2019:108; 78-87.